Diabetic retinopathy and blockade of the renin-angiotensin system: New data from the DIRECT study programme

Eye

Volumn 24, Issue 1, 2010, Pages 1-6

  Wright, A D ^a   Dodson, P M ^a,b  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b ASTON UNIVERSITY   (United Kingdom)

Author keywords

Candesartan; Diabetic retinopathy; DIRECT, EUCLID and RASS studies; Lisinopril; Renin angiotensin blockade

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATENOLOL; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FENOFIBRATE; LISINOPRIL; LOSARTAN; NISOLDIPINE; PERINDOPRIL; PLACEBO; RAMIPRIL;

BLOOD GLUCOSE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE COURSE; DISEASE SEVERITY; DRUG INHIBITION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; POST HOC ANALYSIS; PROPHYLAXIS; REMISSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TREATMENT OUTCOME;

EID: 75449093415     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2009.189     Document Type: Review

References (23)

1. Dodson PM. Diabetic retinopathy. In: Vora J (ed). Hot Topics in Diabetes, 2nd ed. Synergy Press: Richmond, UK, 2009, pp 49-60.
2. Fong DS, Ferris FL, Aiello LP, Klein R. Diabetic retinopathy. Diabetes Care 2004; 27: 2540-2553.
3. Joussen A, Smyth N, Niessen C. Pathophysiology of diabetic macular edema. Dev Ophthalmol 2007; 39: 1-12.
4. Alder VA, Su EN, Yu DY, Cringle S, Yu P. Overview of studies on metabolic and vascular regulatory changes in early diabetic retinopathy. Aust NZ J Ophthalmol 1998; 26: 141-148.
5. Dodson PM. Management of diabetic retinopathy: could lipid-lowering be a worthwhile modality? Eye 2009; 23: 997-1003.
6. Nguyen QD, Tatlipinar S, Shah SM, Haller JA, Quinlan E, Sung J et al Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 2006; 142: 961-969.
7. Danser AH, van den Dorpel MA, Deinum J, Derkx FH, Franken AA, Peperkamp E et al. Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. J Clin Endocrinol Metab 1989; 68: 160-167.
8. Sarlos S, Rizkaller B, Moravski CJ, Cao Z, Cooper ME, Wikubson-Berka JL. Retinal angiogenesis is mediated by an interaction between the angiotensin type 2 receptor, VEGF and angiopoietin. Am J Path 2003; 163: 879-887.
9. Wilkinson-Berka JL. Angiotensin and diabetic retinopathy. Int J Biochem Cell Biol 2006; 38: 752-765.
10. DCCT Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 1995; 44: 968-983.
11. UK Prospective Diabetes Study (UKPDS). Effect of intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998; 352: 837-854.
12. UK Prospective Diabetes Study (UKPDS) Group. Risks of progression and vision loss related to tight blood pressure control in type 2 diabetes. Arch Ophthalmol 2004; 122: 1631-1640.
13. Keech AC, Mitchell P, Summanen PA, O'Day J, Davis TM, Moffitt MS et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised, controlled trial. Lancet 2007; 370: 1687-1697.
14. Action to Control Cardiovascular Risk in Diabetes Study GroupGerstein HC, Miller ME, Byington RP, Goff Jr DC, Bigger JT, Buse JB et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
15. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New Engl J Med 2008; 358: 2560-2572.
16. Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, et al. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial). Lancet 2007; 370: 829-840.
17. Chaturvedi N, Sjolie A-K, Stephenson JM, Abrahamian H, Keipes M, Castellarin A et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 1998; 351: 28-31.
18. Estacio RO, Gifford N, Jeffers BW, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetic Care 2000; 23(suppl.2): B54-B64.
19. Heart outcomes Prevention Evaluation Study Investigators. HOPE Study. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus, results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259.
20. Barnett AH, Bain SC, Bouter P, Karlberg B, Madshad S, Jervell J et al. Angiotensin-receptor blockade versus converting enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351: 1952-1961.
21. Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet 2008; 372: 1394-1402.
22. Sjølie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo controlled trial. Lancet 2008; 372: 1385-1393.
23. Mauer M, Zinman B, Gardiner R, Suissa S, Sinaiko A, Strand T et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009; 361: 40-51.